What REGN ultimately might need is a trial with "as-needed" Lucentis vs. "as-needed" trap. I suspect that the trap would require significantly fewer injections over a multi-year period.
Exactly right, IMO. I’ve been saying for years that REGN’s AMD program was aiming too low, and I think this is now clear.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.